stockrowInhibikase Therapeutics, Inc. (IKT) vs Palisade Bio, Inc. (PALI)
- Inhibikase Therapeutics, Inc. IKT 1.50 +4.17%
- Palisade Bio, Inc. PALI 1.13 −2.59%
Inhibikase Therapeutics, Inc. and Palisade Bio, Inc. are both Biotechnology companies. Inhibikase Therapeutics, Inc. and Palisade Bio, Inc. are of similar size ($202.2M and $200.9M). Inhibikase Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Palisade Bio, Inc. trades at 1.8×. Palisade Bio, Inc. grew revenue faster over the last twelve months: 5,492.6% against 110.9%. Inhibikase Therapeutics, Inc. has the higher net margin (0.00% vs −4,230.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Palisade Bio, Inc. leads on 10 and Inhibikase Therapeutics, Inc. on 6.
Valuation
Profitability
| Metric | IKT | PALI | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 95.63% | 68.51% |
| Operating margin | 0.00% | (4,681.99%) | 0.00% |
| Net margin | 0.00% | (4,230.60%) | 0.00% |
| Free cash flow margin | 0.00% | (2,409.27%) | 0.00% |
| Return on equity | (51.96%) | (51.37%) | (51.96%) |
| Return on assets | (48.04%) | (47.68%) | (46.06%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack